capecitabine and trastuzumab

DRUG2 trials

Sponsors

Fudan University

Conditions

Breast Cancer

Phase 2

Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS)

Active, not recruitingNCT04383275

Fudan UniversityBreast Cancer

Start: 2020-05-20End: 2031-07-06Updated: 2026-08-19

Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS-C/D)

Not yet recruitingNCT04922008

Fudan UniversityBreast Cancer

Start: 2021-07-01End: 2026-06-30Target: 356Updated: 2021-06-10

Related Papers

Adjuvant capecitabine and trastuzumab for stage IA HER2-positive breast cancer (IRIS-A): A phase II clinical trial.

Journal of Clinical Oncology2026-05-27